The TRAIL apoptotic pathway in cancer onset, progression and therapy

被引：714

作者：

Johnstone, Ricky W. ^{[1
]}

Frew, Ailsa J. ^{[1
]}

Smyth, Mark J. ^{[1
]}

机构：

[1] Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic 3002, Australia

来源：

NATURE REVIEWS CANCER | 2008年 / 8卷 / 10期

基金：

英国医学研究理事会;

关键词：

D O I：

10.1038/nrc2465

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Triggering of tumour cell apoptosis is the foundation of many cancer therapies. Death receptors of the tumour necrosis factor (TNF) superfamily have been largely characterized, as have the signals that are generated when these receptors are activated. TNF-related apoptosis-inducing ligand (TRAIL) receptors (TRAILR1 and TRAILR2) are promising targets for cancer therapy. Herein we review what is known about the molecular control of TRAIL-mediated apoptosis, the role of TRAIL in carcinogenesis and the potential therapeutic utility of recombinant TRAIL and agonistic antibodies against TRAILR1 and TRAILR2.

引用

页码：782 / 798

页数：17

共 216 条

[1] Apoptosis control by death and decoy receptors [J].

Ashkenazi, A ;

Dixit, VM .

CURRENT OPINION IN CELL BIOLOGY, 1999, 11 (02) :255-260

[2] Safety and antitumor activity of recombinant soluble Apo2 ligand [J].

Ashkenazi, A ;

Pai, RC ;

Fong, S ;

Leung, S ;

Lawrence, DA ;

Masters, SA ;

Blackie, C ;

Chang, L ;

McMurtrey, AE ;

Hebert, A ;

DeForge, L ;

Koumenis, IL ;

Lewis, D ;

Harris, L ;

Bussiere, J ;

Koeppen, H ;

Shahrokh, Z ;

Schwall, RH .

JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162

[3] Targeting death and decoy receptors of the tumour-necrosis factor superfamily [J].

Ashkenazi, A .

NATURE REVIEWS CANCER, 2002, 2 (06) :420-430

[4] Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening [J].

Aza-Blanc, P ;

Cooper, CL ;

Wagner, K ;

Batalov, S ;

Deveraux, QL ;

Cooke, MP .

MOLECULAR CELL, 2003, 12 (03) :627-637

[5] Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects [J].

Baader, E ;

Toloczko, A ;

Fuchs, U ;

Schmid, I ;

Beltinger, C ;

Ehrhardt, H ;

Debatin, KM ;

Jeremias, I .

CANCER RESEARCH, 2005, 65 (17) :7888-7895

[6] Predominant Bcl-XL knockdown disables antiapoptotic mechanisms:: Tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro [J].

Bai, JR ;

Sui, JH ;

Demirjian, A ;

Vollmer, CM ;

Marasco, W ;

Callery, MP .

CANCER RESEARCH, 2005, 65 (06) :2344-2352

[7] Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL [J].

Belka, C ;

Schmid, B ;

Marini, P ;

Durand, E ;

Rudner, J ;

Faltin, H ;

Bamberg, M ;

Schulze-Osthoff, K ;

Budach, W .

ONCOGENE, 2001, 20 (17) :2190-2196

[8] Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin [J].

Belyanskaya, Larisa L. ;

Marti, Thomas M. ;

Hopkins-Donaldson, Sally ;

Kurtz, Stefanie ;

Felley-Bosco, Emanuela ;

Stahel, Rolf A. .

MOLECULAR CANCER, 2007, 6 (1)

[9] Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding [J].

Bin, Lianghua ;

Thorburn, Jacqueline ;

Thomas, Lance R. ;

Clark, Peter E. ;

Humphreys, Robin ;

Thorburn, Andrew .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (38) :28189-28194

[10] A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells [J].

Bockbrader, KM ;

Tan, MJ ;

Sun, Y .

ONCOGENE, 2005, 24 (49) :7381-7388

← 1 2 3 4 5 6 7 8 9 10 →